Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind Naltrexone in Kleptomania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. men and women age 21-75~2. current DSM-IV kleptomania.~Exclusion Criteria:~1. unstable medical illness or clinically significant abnormalities on prestudy laboratory tests or physical examination~2. history of seizures~3. myocardial infarction within 6 months~4. current pregnancy or lactation, or inadequate contraception in women of childbearing potential~5. clinically significant suicidality~6. current or recent (past 3 months) DSM-IV substance abuse or dependence~7. illegal substance within 2 weeks of study initiation~8. initiation of psychotherapy or behavior therapy from a mental health professional for the treatment of kleptomania within 3 months prior to study baseline~9. initiation of a psychotropic medication within 2 months prior to study inclusion~10. previous treatment with naltrexone~11. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Naltrexone
- B (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).